Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer

(2022) Sejin Kim et al.   Journal of Cancer

Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability

(2022) Jenna Cleyle et al.   MOLECULAR & CELLULAR PROTEOMICS

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody

(2021) Shiwen Peng et al.   mBio

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities

(2021) Leona Yamamoto et al.   Frontiers in Oncology

mRNA vaccine for cancer immunotherapy

(2021) Lei Miao et al.   Molecular Cancer

Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice

(2021) Elodie Belnoue et al.   Cancers

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

(2021) D. G. Roy et al.   Nature Communications

Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.

(2021) Yoshiki Arakawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention

(2021) Lauren R. Corulli et al.   Frontiers in Immunology

Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model

(2021) Johannes Gebert et al.   GASTROENTEROLOGY

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update

(2020) Jan Dörrie et al.   Pharmaceutics

Opportunities and Challenges in the Delivery of mRNA-Based Vaccines

(2020) Abishek Wadhwa et al.   Pharmaceutics

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

(2020) Rong En Tay et al.   CANCER GENE THERAPY

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

(2020) Qianqian Ni et al.   Science Advances

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

(2020) Yanina Jansen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters

(2020) Inken Salewski et al.   Journal of Translational Medicine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Turning the corner on therapeutic cancer vaccines

(2019) Robert E. Hollingsworth et al.   npj Vaccines

Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma

(2019) Tanner M. Johanns et al.   OncoImmunology

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

(2019) Piotr S. Kowalski et al.   MOLECULAR THERAPY

Targeting Tumor Microenvironment for Cancer Therapy

(2019) Catarina Roma-Rodrigues et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cancer DNA vaccines: current preclinical and clinical developments and future perspectives

(2019) Alessandra Lopes et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

(2019) Marit M. Melssen et al.   Journal for ImmunoTherapy of Cancer

Neoantigen vaccine: an emerging tumor immunotherapy

(2019) Miao Peng et al.   Molecular Cancer

A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model

(2019) Zhibing Lin et al.   Molecular Therapy-Oncolytics

A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention

(2019) Jie Chen et al.   Cancers

A large peptidome dataset improves HLA class I epitope prediction across most of the human population

(2019) Siranush Sarkizova et al.   NATURE BIOTECHNOLOGY

Targeting the microenvironment in solid tumors

(2018) Carmen Belli et al.   CANCER TREATMENT REVIEWS

Hitting the Target: How T Cells Detect and Eliminate Tumors

(2018) Anthony E. Zamora et al.   JOURNAL OF IMMUNOLOGY

Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report

(2018) Katja Sonntag et al.   Journal of Translational Medicine

mRNA vaccines — a new era in vaccinology

(2018) Norbert Pardi et al.   NATURE REVIEWS DRUG DISCOVERY

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Actively personalized vaccination trial for newly diagnosed glioblastoma

(2018) Norbert Hilf et al.   NATURE

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

(2016) Sofie Wilgenhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

(2016) Lena M. Kranz et al.   NATURE

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

(2016) Marios Giannakis et al.   Cell Reports

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines

(2016) Spencer D. Martin et al.   PLoS One

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients

(2015) Maria Grazia Cusi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates

(2015) Elizabeth A. Thompson et al.   JOURNAL OF IMMUNOLOGY

In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

(2015) Geoffrey M Lynn et al.   NATURE BIOTECHNOLOGY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients

(2015) Pierpaolo Correale et al.   OncoImmunology

DNA vaccine for cancer immunotherapy

(2015) Benjamin Yang et al.   Human Vaccines & Immunotherapeutics

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

(2014) M. Rajasagi et al.   BLOOD

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases

(2014) Sofie Wilgenhof et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: To use or not to use?

(2014) Marius M. Strioga et al.   VACCINE

HLA-Binding Properties of Tumor Neoepitopes in Humans

(2014) E. F. Fritsch et al.   Cancer Immunology Research

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

(2013) S. Wilgenhof et al.   ANNALS OF ONCOLOGY

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides

(2013) Lei Diao et al.   CLINICAL PHARMACOKINETICS

Comparison of Vaccine-Induced Effector CD8 T Cell Responses Directed against Self- and Non-Self-Tumor Antigens: Implications for Cancer Immunotherapy

(2013) S. R. Pedersen et al.   JOURNAL OF IMMUNOLOGY

HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies

(2013) Diana P. English et al.   Molecular Diagnosis & Therapy

Maraba Virus as a Potent Oncolytic Vaccine Vector

(2013) Jonathan G Pol et al.   MOLECULAR THERAPY

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

A novel, disruptive vaccination technology

(2013) Karl-Josef Kallen et al.   Human Vaccines & Immunotherapeutics

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Whole Cell Vaccines—Past Progress and Future Strategies

(2012) Bridget P. Keenan et al.   SEMINARS IN ONCOLOGY

The Present and Future of Peptide Vaccines for Cancer

(2011) Craig L. Slingluff   CANCER JOURNAL

Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma

(2011) Sofie Wilgenhof et al.   JOURNAL OF IMMUNOTHERAPY

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

(2011) Neil Senzer et al.   MOLECULAR THERAPY

Programming the magnitude and persistence of antibody responses with innate immunity

(2011) Sudhir Pai Kasturi et al.   NATURE

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

(2011) Katalin Karikó et al.   NUCLEIC ACIDS RESEARCH

Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans

(2011) Elena Quaglino et al.   Cancers

Parathyroid Hormone-Related Protein (PTHrP): A Key Regulator of Life/Death Decisions by Tumor Cells with Potential Clinical Applications

(2011) Claudio Luparello   Cancers

Cellular Vaccine Approaches

(2010) Dung T. Le et al.   CANCER JOURNAL

Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity

(2010) S. Kreiter et al.   CANCER RESEARCH

Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors

(2010) Kanji Sato et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

(2008) Katalin Karikó et al.   MOLECULAR THERAPY

Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing

(2008) P. J. Campbell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA